On 10/17/25, Neoleukin Therapeutics Inc (NASDAQ: NGNE) stock suffered a major decline of -14.6%, closing at $29.03. Moreover, this decline was accompanied by above average trading volume at 120% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -8.0% during the last week.
Current PriceTarget Research Rating
Neoleukin Therapeutics has a current Value Trend Rating of C (High Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Neoleukin Therapeutics has a poor Appreciation Score of 29 but a good Power Rating of 81, and the High Neutral Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment